In WOMAN trial (World Maternal Antifibrinolytic Trial), tranexamic acid for postpartum hemorrhage reduced death due to bleeding when administered within:

• A 30 minutes of diagnosis
• B 3 hours of delivery ✓
• C 1 hour of diagnosis
• D 6 hours of delivery

Explanation

The WOMAN trial (Lancet, 2017) showed that tranexamic acid (1g IV) significantly reduced death from bleeding in postpartum hemorrhage when given within 3 hours of delivery, with the greatest effect when given within 1 hour. Giving it after 3 hours provided no mortality benefit. This established the 3-hour window as the critical treatment threshold, analogous to the CRASH-2 trial findings in trauma. It did not reduce thromboembolic complications.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.